Fiche société
Genentech, Inc.
Traitements, essais et publications liés.
Traitements19programmes
Essais14liés
Publications22liées
SourceDBlocale
Traitements
19| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Asthma therapiesThis was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study. | SEP | Phase 4 | À vérifier | United States | À vérifier |
| BevacizumabThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Cancer, Parkinson | Phase 2 | À vérifier | United States, Puerto Rico | À vérifier |
| CevostamabThe study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN). | Lupus | Phase 1 | À vérifier | Australia, Brazil, China, France, Italy, Spain | À vérifier |
| DulanerminThis Phase Ib/II, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and efficacy of dulanermin when combined with rituximab in subjects with follicular, CD20+, B-cell Non-Hodgkin's Lymphoma (NHL) that has progressed following a response of ≥ 6 months duration to a prior rituximab-containing therapy. The multicenter, international, randomized Phase II part of this study will commence only after the safety and available pharmacokinetic data from the Phase Ib part of the study have been evaluated by the Sponsor and have been provided to participating investigators and the FDA. | SEP | Phase 1/2 | Immunomodulation | À vérifier | |
| OCR SCThe purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV). | SEP | Phase 4 | Immunomodulation | United States, Puerto Rico | À vérifier |
| OmalizumabThis was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study. | SEP | Phase 4 | À vérifier | United States | À vérifier |
| P-CD19CD20-ALLO1 CellsThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | Lupus, SEP | Phase 1 | Immunomodulation | United States | À vérifier |
| RimiducidThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | Lupus | Phase 1 | Immunomodulation | United States | À vérifier |
| TocilizumabThe purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part. | Accident vasculaire cérébral, Cancer, Épilepsie, Lupus | Phase 1 | À vérifier | Australia, Brazil, China, France, Italy, Spain | À vérifier |
| BevacizumabThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| OCR SCThe purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered subcutaneously (SC) in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS) after switching from another anti-cluster of differentiation 20 (aCD20) therapy approved for RMS (ofatumumab SC, ublituximab-xiiy intravenous \[IV\], ocrelizumab IV) or PPMS (ocrelizumab IV). | SEP | Phase 4 | Immunomodulation | United States, Puerto Rico | À vérifier |
| CevostamabThe study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cevostamab in participants with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN). | Lupus | Phase 1 | À vérifier | Australia, Brazil, China, France, Italy, Spain | À vérifier |
| P-CD19CD20-ALLO1 CellsThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | Lupus | Phase 1 | Immunomodulation | United States | À vérifier |
| BevacizumabThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
| OmalizumabThis was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study. | SEP | Phase 4 | À vérifier | United States | À vérifier |
| P-CD19CD20-ALLO1 CellsThe purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1. | SEP | Phase 1 | Immunomodulation | United States | À vérifier |
| TocilizumabThe purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RO7507062 in participants with systemic lupus erythematosus (SLE). The study will have 2 parts: Part 1 is a single ascending dose-finding (SAD) part and Part 2 is a dose escalation with fractionated dosing part. | Accident vasculaire cérébral | Phase 3 | À vérifier | China | À vérifier |
| BevacizumabThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Cancer | Phase 3 | À vérifier | United States | À vérifier |
| DulanerminThis Phase Ib/II, open-label, multicenter trial is designed to evaluate the safety, pharmacokinetics, and efficacy of dulanermin when combined with rituximab in subjects with follicular, CD20+, B-cell Non-Hodgkin's Lymphoma (NHL) that has progressed following a response of ≥ 6 months duration to a prior rituximab-containing therapy. The multicenter, international, randomized Phase II part of this study will commence only after the safety and available pharmacokinetic data from the Phase Ib part of the study have been evaluated by the Sponsor and have been provided to participating investigators and the FDA. | SEP | Phase 1/2 | Immunomodulation | À vérifier |
Essais cliniques
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Atezolizumab | Cancer | Phase 2 | NCT06096779 | Kirros — A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | ACTIVE_NOT_RECRUITING |
| Dulanermin | SEP | Phase 1/2 | NCT00400764 | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas | TERMINATED |
| Bevacizumab | Cancer | Phase 3 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING |
| Tocilizumab | Accident vasculaire cérébral | Phase 3 | NCT07509645 | IRIS-3 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke | RECRUITING |
| P-CD19CD20-ALLO1 Cells | SEP | Phase 1 | NCT07008378 | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT02637856 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Omalizumab | SEP | Phase 4 | NCT01125748 | XPORT — A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy | COMPLETED |
| Ocrelizumab | SEP | Phase 4 | NCT04377555 | Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab | COMPLETED |
| Bevacizumab | Cancer | Phase 2 | NCT05797246 | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| P-CD19CD20-ALLO1 Cells | Lupus | Phase 1 | NCT06984341 | A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) | WITHDRAWN |
| Cevostamab | Lupus | Phase 1 | NCT07629583 | To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis | RECRUITING |
| OCR SC | SEP | Phase 4 | NCT07609719 | OSSIA — A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy | RECRUITING |
| Bevacizumab | Cancer | Phase 2 | NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | COMPLETED |
Publications
22| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Rimiducid | Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. | Cancer gene therapy | ||
| Cevostamab | Atypical Lymphocytosis Induced by T Cell-Engaging Therapy in Patients With Hematological Malignancies. | International journal of laboratory hematology | ||
| Tocilizumab | A curious case of generalized pruritus in giant cell arteritis. | JAAD case reports | ||
| Tocilizumab | A Case of Cytokine Release Syndrome (CRS) Related to Treatment With Lenvatinib Plus Pembrolizumab for Metastatic Clear Cell Renal Cell Carcinoma. | IJU case reports | ||
| Tocilizumab | An antibody-conjugated polymer nanoparticle that targets inflammatory site for abdominal aortic aneurysm antioxidant stress therapy. | Biomaterials advances | ||
| Bevacizumab | Bevacizumab induces apoptosis in glioblastoma cells by upregulating miR-4695-5p to inhibit PKMYT1. | RNA biology | ||
| Bevacizumab | Single-cell transcriptome-guided biomimetic magnetothermal hydrogel microspheres for multimodal eradication of residual glioblastoma. | Bioactive materials | ||
| Bevacizumab | Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China. | Human vaccines & immunotherapeutics | ||
| Rimiducid | PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. | Nature communications | ||
| Rimiducid | GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. | Nature medicine | ||
| Cevostamab | Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park, N.Y.) | ||
| Cevostamab | FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. | Nature medicine | ||
| Tocilizumab | Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome. | International journal of molecular sciences | ||
| Bevacizumab | Impact of Bevacizumab Relative Dose Intensity and Treatment-Induced Proteinuria on the Efficacy of Trifluridine/Tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer. | Cancers | ||
| OCR SC | Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. | Neurology | ||
| Tocilizumab | Regulatory T cell modulation with selective CD28 blockade and IL-6 receptor antagonist in kidney transplant recipients: results of CTOT-24, a prospective clinical trial. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons | ||
| Bevacizumab | Treatment-Emergent Isolated EGFR C797S Mutation Following First-Line Osimertinib-Based Combination Therapy: A Case Report and Literature Review. | Respirology case reports | ||
| Bevacizumab | Mechanistic synergies and optimal sequencing of anti‑VEGF plus immune checkpoint inhibition in gastrointestinal cancers. | Discover oncology | ||
| Bevacizumab | Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States. | Gynecologic oncology | ||
| Bevacizumab | Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab. | Annals of surgical oncology | ||
| Bevacizumab | Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma. | Nature communications | ||
| Bevacizumab | Intra-articular VEGF inhibition attenuates cartilage degeneration in a rat model of post-traumatic osteoarthritis: a pilot histopathological study. | Rheumatology international |